South Korean civil society groups welcome the ruling of the Supreme Court of...
[Novartis defeated in its appeal trial, a triumphant victory of World patients fighting back Patent Exclusivity] Welcome the ruling of the Supreme Court of India 1. The protracted Novartis’ appeal from...
View ArticleApex court right to reject Novartis’s attempt
Novartis threat that it would not introduce new medicines in India after the verdict is hollow, says Anand Grover. While the patients and the generic companies have rejoiced over the Supreme Court’s...
View ArticleAttack on affordable medicines continues in EU-India trade negotiations
Attack on affordable medicines continues in EU-India trade negotiations Health groups rally in Delhi as protests spread across the developing world 10 April, 2013, New Delhi- Thousands of people...
View ArticleIndia’s Patently Wise Decision
The Indian Supreme Court’s refusal to uphold the patent on Gleevec, the blockbuster cancer drug developed by the Swiss pharmaceutical giant Novartis, is good news for many of those in India suffering...
View ArticleNovartis Ruling Reverberates Past India’s Borders
India’s Supreme Court says drug maker Novartis can’t hold onto its patent for the pricey cancer drug Gleevec simply by tweaking its chemical formula. That means generic drug makers can keep making a...
View ArticleIndia’s patent case victory rattles Big Pharma
Will India, the world’s biggest provider of low-cost generic medicines, be the pariah or the pioneer of the pharmaceutical world? There is renewed focus on this thorny question in the wake of India’s...
View ArticleWhy Novartis case will help innovation
The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board’s...
View ArticleIndian Patent Law TRIPS Compliant: Novartis judgment shows the way
While patients groups around the world have expressed joy over the Novartis decision of the Supreme Court of India, western Multi National Companies (MNCs) and their governments have expressed extreme...
View ArticleRights: Access to medicines resolution adopted
New Delhi, 15 Jul (K. M. Gopakumar) — The United Nations Human Rights Council has adopted a resolution on access to medicines despite opposition from the United States and the European Union. This was...
View ArticleMore than safety, location of a nuclear plant should be considered first: Lawyer
COIMBATORE: A three-day national consultation committee on HIV/AIDS care and support to the patients, organised at the Karl Kubel Institute here in Annaikatti, concluded on Saturday. Among the speakers...
View ArticleAnalysing the Supreme Court Judgment
Vol – XLVIII No. 32, August 10, 2013 | Anand Grover A detailed account of the examination of Section 3(d) of the Indian Patents Act in the Supreme Court’s judgment on Novartis’s patent application for...
View ArticleLawyers Collective Response to Testimony of Mr. Roy F Waldron, Pfizer Inc.
Recently, several multinational pharmaceutical companies along with the US Chamber of Commerce have been instrumental in mounting pressure on India to decry the alleged state of Intellectual Property...
View ArticlePatent challenge
IT has been more than a year since the first compulsory licence was granted to an Indian company manufacturing generic drugs to produce a patented drug. In March 2012, the compulsory licence granted to...
View ArticleValganciclovir: IPAB remands matter back to the Controller: patent to remain...
30th January, 2014: The Intellectual Property Appellate Board (IPAB) set aside the Patent Controller’s decision to revoke the patent relating to valganciclovir on technical grounds and remanded it to...
View ArticleNaz Foundation files Curative Petition challenging the Supreme Court judgment...
31st March, 2014: The Naz Foundation (India) Trust, the original petitioner in the constitutional challenge to Section 377, has filed a curative petition challenging the Supreme Court decision in...
View ArticleIndian Civil Society Members Urge Prime Minister to Resist US Administration...
March 27, 2014 Dr. Manmohan Singh Hon’ble Prime Minister of India, The Prime Minister’s Office, South Block, Raisina Hill, New Delhi 110011. Tel: 011 23018939; Fax: 011 2301 0233. Email:...
View ArticleBombay High Court dismisses Bayer’s challenge- upholds Compulsory license on...
15.07.2014- In a momentous decision for patients, a Division Bench of the Bombay High Court dismissed a writ petition filed by Bayer challenging the IPAB order upholding the compulsory license granted...
View ArticleCivil society opposes patent on sofosbuvir
10 September, 2014- In a move towards furthering access to affordable medicines, Lawyers Collective through Sankalp Rehabilitation Trust, the Hepatitis Coalition of Nagaland and Network of PLHIV living...
View ArticleSupreme Court says no to Bayer, upholds compulsory license on Nexavar
December 12, 2014 In a momentous decision that would have wide-ranging implication for access to medicines, the Supreme Court of India refused to entertain Bayer’s appeal to set aside the compulsory...
View ArticleRights: Access to medicines resolution adopted
New Delhi, 15 Jul (K. M. Gopakumar) — The United Nations Human Rights Council has adopted a resolution on access to medicines despite opposition from the United States and the European Union. This was...
View Article
